Advances in pharmacotherapy for hyperphosphatemia in renal disease

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 17, 2015, Pages 2589-2599

  Spasovski, Goce ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

Author keywords

calcium based phosphate binders; chronic kidney disease; chronic kidney diseasemineral and bone disorders; hyperphosphatemia; non calcium based phosphate binders

Indexed keywords

CALCIUM; CALCIUM ACETATE; CALCIUM BASED PHOSPHATE BINDER; CALCIUM CARBONATE; COLESTILAN; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; NICOTINIC ACID; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG; PHOSPHATE;

BLOOD VESSEL CALCIFICATION; CALCIUM BALANCE; CHRONIC KIDNEY DISEASE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHOSPHATE BALANCE; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; REVIEW; RISK REDUCTION; BLOOD; COMPLICATION; DISEASE COURSE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; VASCULAR CALCIFICATION;

DISEASE PROGRESSION; HUMANS; HYPERPHOSPHATEMIA; PHOSPHATES; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84951907772     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1092521     Document Type: Review

References (91)

1. Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012;23(7):1258-70
2. Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients. Nephrol Dial Transplant 2007;22:2909-16
3. Vanholder R, Baurmeister U, Brunet P, et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008;19(5):863-70
4. Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial 2009;22(4):357-62
5. Spasovski G. A review of sevelamer hydrochloride in end-stage renal disease patients on dialysis. Clinical Medicine Insights: Therapeutics 2011:3:51-5
6. Goto S, Komaba H, Fukagawa M, Nishi S. Optimizing the cost-effectiveness of treatment for chronic kidney diseasemineral and bone disorder. Kidney Int Suppl 2013;3:457-61
7. Moe SM, Drueke TB, Block GA, et al. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int 2009;76:S1-S130
8. Ketteler M, Elder GJ, Evenepoel P, et al. Revisiting KDIGO clinical practice guideline on chronic kidney diseasemineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2015;87(3):502-28
9. National Kidney Foundation. K/DOQI, NKF: clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201
10. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33(4):694-701
11. Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994;46:855-61
12. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62(1):245-52
13. Zoccali C, Abramowicz D, Cannata-Andia JB, et al. European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrol Dial Transplant 2008;23:2162-6
14. Goldsmith DJ, Covic A, Fouque D, et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010;25(12):3823-31
15. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010;55(5):773-99
16. Manns BJ, Hodsman A, Zimmerman DL, et al. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010;55(5):800-12
17. London G, Coyne D, Hruska K, et al. The new kidney disease: improving global outcomes (KDIGO) guidelines-expert clinical focus on bone and vascular calcification. Clin Nephrol 2010;74(6):423-32
18. Spasovski GB. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 2007;39(4):1209-16
19. Spasovski G, Gelev S, Masin-Spasovska J, et al. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone 2007;41(4):698-703
20. Spasovski G. New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease. Recent Patents Cardiovasc Drug Discov 2008;3(3):222-8
21. Farkouh ME, Fuster V. Meta-analysis of small trials: proceed with caution. Nat Clin Pract Nephrol 2008;4:115
22. Tonelli M, Wiebe N, Culleton B, et al. Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007;22:2856-66
23. Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007;22(10):2867-78
24. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71(5):438-41
25. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72(9):1130-7
26. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51(3):445-54
27. Ferreira A, Frazaõ JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19(2):405-12
28. Assimon MM, Mousa S, Shaker O, Pai AB. The effect of sevelamer hydrochloride and Calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research. Consult Pharm 2010;25(1):41-54
29. Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009;24(10):3168-74
30. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
31. Barreto DV, Barreto FD, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC Study. Nephron Clin Pract 2008;110:c273-83
32. Shantouf R, Ahmadi N, Flores F, et al. Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol 2010;74(1):12-18
33. Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010;25(8):2672-9
34. Zhang Q, Li M, Lu Y, et al. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 2010;115(4):c259-67
35. Fishbane S, Delmez J, Suki WN, et al. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thricedaily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis 2010;55(2):307-15
36. De Francisco AL, Leidig M, Covic A, et al. Evaluation of calcium acetate/ magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol DialTransplant 2010;25:3707-17
37. Spasovski G, Vanholder R. Is combined calcium/magnesium phosphate binder really non-inferior to sevelamer hydrochloride? Nephrol DialTransplant 2011;26(4):1442-3
38. Negri AL. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? J Nephrol 2010;23(6):653-7
39. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int 2007;71:312-17
40. Bover J, Evenepoel P, Urenã-Torres P, et al. Opponent's comments. Nephrol Dial Transplant 2015;30(3):357
41. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77
42. Navaneethan SD, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011;(2):CD006023
43. Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphatebinding agents is associated with a lower risk of mortality. Kidney Int 2013;84(5):998-1008
44. Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013;83:959-66
45. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-15
46. Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7:487-93
47. Oliveira RB, Cancela AL, Graciolli FG, et al. Early Control of PTH and FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy? Clin J Am Soc Nephrol 2010;5(2):286-91
48. De Broe ME, Coburn JW. Aluminum and Renal Failure. In: Developments in Nephrology Kluwer Acad Publ, Dordrecht; 1990. p. 99-375
49. Sheikh MS, Maquire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989;83(1):66-73
50. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
51. CARE. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26
52. Jean G, Lataillade D, Genet L, et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 2011;15:485-92
53. Qunibi W, Moustafa et al. Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51(6):952-65
54. Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008;3:1125-30
55. Savica V, Santoro D, Monardo P, et al. Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag 2008;4(4):821-6
56. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
57. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
58. Hutchison AJ, Laville M; On behalf of the SPD405-313 lanthanum study group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008;23(11):3677-84
59. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003;85:S73-8
60. Sakurada T, Oishi D, Shibagaki et al. et al.. Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients. Hemodial Int 2013;17(Suppl 1):S2-6
61. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) 2011;16(3):290-8
62. Lacour B, Lucas A, Auche're D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005;67:1062-9
63. Hutchison AJ, Barnett ME, Krause R, et al. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol 2009;71:286-95
64. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21(8):2217-24
65. Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009;25(12):3021-8
66. de Francisco MAL, Rodriquez M. Magnesium-its role in CKD. Nefrologia 2013;33(3):389-99
67. Liabeuf S, Okazaki H, Desjardines L, et al. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant 2014;29(7):1275-84
68. Shanahan CM. Vascular calcification. Curr Opin Nephrol Hypertens 2005;14:361-7
69. Sakagushi Y, Fujii N, Shoji T, et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS ONE 2014;9(12):e116273
70. Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011;7(6):578-89
71. Guillot AP, Hood VL, Runge CF, Gennari FJ. The use of magnesiumcontaining phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron 1982;30(2):114-17
72. Tzanakis IP, Papadaki AN, Wei M, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008;40(1):193-201
73. Massy ZA, Drueke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 2012;5(Suppl 1):i52-61
74. Locatelli F, Dimkovic N, Pontoriero G, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in hemodialysis patients with hyperphosphatemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 2010;25(2):574-81
75. Hertel J, Locatelli F, Spasovski G, et al. Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia. Nephron 2015;in press
76. Locatelli F, Spasovski G, Dimkovic N, et al. The effects of Colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphatemia: a 1-year prospective randomized study. Nephrol Dial Transplant 2014;29(5):1061-73
77. Locatelli F, Dimkovic N, Spasovski G. Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. Expert Opin Pharmacother 2014;15(10):1475-88
78. Wuthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the ironbased phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8:280-9
79. Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014;86(3):638-47
80. Dwyer JP, Sika M, Schulman G, et al. Collaborative Study Group. Dose response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 2013;61:759-66
81. Floege J, Covic AC, Ketteler M, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 2015;30(6):1037-46
82. Mutell R, Rubin J, Bond T, et al. Reduced use of erythropoiesis stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis 2013;6:79-87
83. Thomas A, Peterson LE. Reduction of costs for anemiamanagement drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis 2014;7:191-201
84. Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel) 2014;7:990-8
85. Shin S, Lee S. Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients. Ther Clin Risk Manag 2014;10:875-83
86. Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8
87. Maccubbin D, Tipping D, Kuznetsova O, et al. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 2010;5:582-9
88. Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65(3):1099-104
89. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009;4:1089-96
90. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008;9:2
91. Arenas MD, Malek T, Gil MT, et al. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 2010;23(5):525-34